The estimated Net Worth of Michael S Wyzga is at least $8.93 Million dollars as of 18 August 2023. Mr. Wyzga owns over 25,000 units of Exact Sciences stock worth over $4,915,888 and over the last 11 years he sold EXAS stock worth over $3,678,627. In addition, he makes $331,023 as Independent Director at Exact Sciences.
Sign up
Mr. Wyzga EXAS stock SEC Form 4 insiders trading
Michael has made over 8 trades of the Exact Sciences stock since 2014, according to the Form 4 filled with the SEC. Most recently he bought 25,000 units of EXAS stock worth $30,000 on 18 August 2023.
The largest trade he's ever made was buying 25,000 units of Exact Sciences stock on 18 August 2023 worth over $30,000. On average, Michael trades about 1,779 units every 95 days since 2014. As of 18 August 2023 he still owns at least 76,667 units of Exact Sciences stock.
You can see the complete history of Mr. Wyzga stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Michael Wyzga biography
Michael S. Wyzga serves as Independent Director of the Company. Mr. Wyzga served as the President and Chief Executive Officer and a member of the board of directors of Radius Health, Inc., a biopharmaceutical company focused on developing new therapeutics for the treatment of osteoporosis and other women's health conditions, from December 2011 to November 2013. Prior to that, Mr. Wyzga served in various senior management positions at Genzyme Corporation, a global biotechnology company. Mr. Wyzga joined Genzyme in March 1997 and most recently served as Executive Vice President, Finance from May 2003 until November 2011 and as Chief Financial Officer from July 1999 until November 2011. Mr. Wyzga is an independent healthcare consultant and currently serves as Chairman of the Board of Directors of Gensight Biologics S.A., a clinical-stage biologics company (EPA: SIGHT), Chairman of the Board of Directors of X4 Pharmaceuticals, a biopharmaceutical company (Nasdaq: XFOR), and LogiBio Therapeutics, Inc., a biopharmaceutical company (Nasdaq: LOGC),, and previously served as a director of Prosensa Holding N.V. (formerly Nasdaq: RNA), a biotechnology company, and Idenix Pharmaceuticals, Inc. (formerly Nasdaq: IDIX), a pharmaceutical company. Mr. Wyzga earned a bachelor's degree from Suffolk University and an MBA from Providence College.
What is the salary of Michael Wyzga?
As the Independent Director of Exact Sciences, the total compensation of Michael Wyzga at Exact Sciences is $331,023. There are 19 executives at Exact Sciences getting paid more, with Kevin Conroy having the highest compensation of $18,716,500.
How old is Michael Wyzga?
Michael Wyzga is 65, he's been the Independent Director of Exact Sciences since 2015. There are 4 older and 19 younger executives at Exact Sciences. The oldest executive at Exact Sciences Corp. is James Doyle, 74, who is the Independent Director.
What's Michael Wyzga's mailing address?
Michael's mailing address filed with the SEC is C/O MEREO BIOPHARMA GROUP PLC, 4TH FLOOR, ONE CAVENDISH PLACE, LONDON, X0, W1G 0QF.
Insiders trading at Exact Sciences
Over the last 21 years, insiders at Exact Sciences have traded over $118,141,352 worth of Exact Sciences stock and bought 191,930 units worth $1,451,887 . The most active insiders traders include Kevin T Conroy, Edwin M Jr Kania und Maneesh Arora. On average, Exact Sciences executives and independent directors trade stock every 12 days with the average trade being worth of $1,667,056. The most recent stock trade was executed by Brian Baranick on 5 August 2024, trading 2,712 units of EXAS stock currently worth $173,893.
What does Exact Sciences do?
exact sciences is a molecular diagnostics company focused on colorectal cancer. the company has exclusive intellectual property protecting its non-invasive, molecular screening technology for the detection of colorectal cancer. stool-based dna (sdna) technology is included in the colorectal cancer screening guidelines of the american cancer society and the u.s. multi-society task force on colorectal cancer. for more information on exact sciences' noninvasive colon cancer screening test, visit cologuardtest.com
What does Exact Sciences's logo look like?
Complete history of Mr. Wyzga stock trades at Akebia Therapeutics, Exact Sciences, ContextLogic Inc, X4 Pharmaceuticals und Mereo BioPharma plc
Exact Sciences executives and stock owners
Exact Sciences executives and other stock owners filed with the SEC include:
-
Kevin Conroy,
Chairman of the Board, President, Chief Executive Officer -
Mark Stenhouse,
General Manager - Screening -
Jeffrey Elliott,
Chief Financial Officer -
D. Scott Coward,
Senior Vice President, Chief Administrative Officer, General Counsel, Secretary -
Jake Orville,
General Manager - Pipeline -
Ana Hooker,
Senior Vice President, Operations -
Graham Lidgard,
Senior Vice President, Chief Scientific Officer -
Kevin T. Conroy,
Chairman, Pres & CEO -
G. Bradley Cole,
Gen. Mang. of Precision Oncology -
Mark Stenhouse,
Advisor -
Graham P. Lidgard,
Emeritus Chief Science Officer -
Jeffrey T. Elliott CFA,
Exec. VP, CFO & COO -
D. Scott Coward,
Chief Admin. Officer, Exec. VP, Gen. Counsel & Sec. -
Kathleen Sebelius,
Independent Director -
Andrew Slavitt,
Director -
Pierre Jacquet,
Independent Director -
Jake Orville,
Gen. Mang. of Pipeline -
Ana Hooker,
Sr. VP of Operations -
James Doyle,
Independent Director -
Michael Wyzga,
Independent Director -
Daniel Levangie,
Independent Director -
Katherine Zanotti,
Independent Director -
Thomas Carey,
Independent Director -
Shacey Petrovic,
Director -
Gisela Paulsen,
General Manager - Precision Oncology -
Torsten Hoof,
General Manager - International -
Freda Lewis-Hall,
Independent Director -
Scott Johnson,
Senior Vice President, Research and Development -
Vic Parker,
Head of Sales -
Tim Caprez,
Chief Compliance Counsel & VP -
Megan Jones,
Associate Mang. of Investor Relations -
Dr. Scott C. Johnson Ph.D.,
Chief Science Officer and Sr. VP of R&D -
Gary Frings,
Chief Information Officer -
Lionel Sterling,
Director -
John A. Fallon,
Director -
David Thompson,
Director -
G Bradley Cole,
General Manager - Diagnostics -
Paul J Clancy,
-
Michael J Barber,
-
Eli Casdin,
Director -
Anthony P Shuber,
Executive Vice President -
John A Jr Mccarthy,
Chief Financial Officer -
Don M Hardison,
President, CEO and Director -
Barry M Berger,
SVP, Chief Medical Officer -
William J. Megan,
SVP, Finance & PFO -
John K Bakewell,
Chief Financial Officer -
Jeffrey R Luber,
General Counsel -
Edwin M Jr Kania,
Director -
Charles R Jr Carelli,
Prin. Acct. Off. & Corp. Ctlr. -
Patrick J Zenner,
Director -
Stanley N Lapidus,
Director -
John M Krayacich,
SVP, Sales and Marketing -
Richard W Barker,
Director -
Laura S Stoltenberg,
Chief Commercial Officer -
Cornelius Iii Mcgillicudy,
Director -
Harry W Wilcox,
Senior Vice President and CFO -
Lance Willsey,
Director -
Michael E Singer,
Director -
Maneesh Arora,
Vice President -
James P Connelly,
Director -
Sally Crawford,
Director -
Sarah Condella,
EVP, Human Resources -
Timothy J Scannell,
Director -
James Herriott,
SVP, General Counsel & Sec -
Everett Cunningham,
Chief Commercial Officer -
Jacob A Orville,
EVP, GM, Screening -
Brian Baranick,
EVP, GM, Precision Oncology